Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.48 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717882 | 0.91 | DHODH (0.54) | PDE10ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2718890 | 0.87 | PLA2G2A (0.55) | PDE10ASQORDHODHPIK3CDPIK3CA | |
| SCHEMBL2718336 | 0.81 | PIK3CD (0.48) | DHODHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20081373 | 0.80 | FABP3 (0.44) | DHODHPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2720107 | 0.79 | PIK3CD (0.57) | PDE10ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2720602 | 0.78 | PIK3CD (0.53) | PDE10ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2718205 | 0.77 | PIK3CD (0.55) | SQORPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12974299 | 0.76 | DHODH (0.65) | PDE10ADHODHFABP3FABP4FABP5 | |
| SCHEMBL2718187 | 0.74 | PIK3CD (0.48) | PDE10ADHODHPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2717207 | 0.73 | SMYD3 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-A2 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PDE10A 3201/4885SQOR 3318/4885DHODH 3116/4885 |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PDE10A 3271/4885SQOR 3376/4885DHODH 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.